Novo Nordisk Foundation Symposium
G protein-coupled receptors (GPCRs) are a family of approximately 800 membrane proteins, making them the largest family of membrane proteins in humans. They are involved in most physiological processes, from the basic senses such as vision, smell and taste over hormonal control of development and metabolism to nerve cell communication in the brain.
Given their abundance and critical physiological role, it is not surprising that GPCRs are involved in numerous pathologies as well. Accordingly, they are the target of approximately 30% of all marketed drugs generating aggregated sales of nearly US$183 billion per year in recent years, most of any drug target. In addition to the large impact GPCR research has on healthcare and economy, the investigation of their complex cellular signaling pathways is a major driver in the development of innovative tools, techniques and concepts with applications that often extend far beyond the GPCR community.
The aim of this symposium is to bring together some of the most outstanding academic and industrial researchers to allow the exchange of knowledge, establishment of collaborations and education of young and experienced researchers about the state-of-the-art of the field with particular focus on novel techniques and concepts.
List of speakers
- Brian K. Kobilka, Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA
- Thue W. Schwartz, NNF Center for Basic Metabolic Research, University of Copenhagen, Denmark
- Jean-Philippe Pin, Institut de Génomique Fonctionnelle, CNRS, INSERM and Université de Montpellier, Montpellier, France
- Amadeu Llebaria, Institute of Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC), Barcelona, Spain
- Mark von Zastrow, Department of Psychiatry and Department of Cellular & Molecular Pharmacology, University of California, San Francisco (UCSF), CA, USA
- Patrick Sexton, The Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Parkville, Australia
- Evi Kostenis, Institute for Pharmaceutical Biology, University of Bonn, Germany
- Davide Calebiro, Institute of Metabolism and Systems Research, University of Birmingham, UK
The final program will be sent to all participants before the symposium, and will also be available at the venue.